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Background: Accumulating evidence indicates that miRNAs play an important role in
the development of amyotrophic lateral sclerosis (ALS). Most of previous studies on
miRNA dysregulation in ALS focused on the alterative expression in ALS animal model
or in limited samples from European patients with ALS. In the present study, the miRNA
expression profiles were investigated in Chinese ALS patients to explore leukocytes
miRNAs as a potential biomarker for the diagnosis of ALS.
Methods: We analyzed the expression profiles of 1733 human mature miRNAs using
microarray technology in leukocytes obtained from 5 patients with sporadic ALS (SALS)
and 5 healthy controls. An independent group of 83 SALS patients, 24 Parkinson’s
disease (PD) patients and 61 controls was used for validation by real-time polymerase
chain reaction assay. Area under the receiver operating characteristic curve (AUC) was
used to evaluate diagnostic accuracy. In addition, target genes and signaling information
of validated differential expression miRNAs were predicted using Bioinformatics.
Results: Eleven miRNAs, including four over-expressed and seven under-expressed
miRNAs detected in SALS patients compared to healthy controls were selected for
validation. Four under-expressed microRNAs, including hsa-miR-183, hsa-miR-193b,
hsa-miR-451, and hsa-miR-3935, were confirmed in validation stage by comparison of
83 SALS patients and 61 HCs. Moreover, we identified a miRNA panel (hsa-miR-183,
hsa-miR-193b, hsa-miR-451, and hsa-miR-3935) having a high diagnostic accuracy of
SALS (AUC 0.857 for the validation group). However, only hsa-miR-183 was significantly
lower in SALS patients than that in PD patients and in HCs, while no differences were
found between PD patients and HCs. By bioinformatics analysis, we obtained a large
number of target genes and signaling information that are linked to neurodegeneration.
Conclusion: This study provided evidence of abnormal miRNA expression patterns
in the peripheral blood leukocytes of SALS patients.Leukocytes miRNAs provide a
promising opportunity for detection of SALS. The specificity of under-expression of
hsa-miR-183 in SALS needs to be confirmed by further miRNA studies on other
neurodegenerative diseases.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a fatal progressive
neurodegenerative disease characterized by degeneration of
motor neurons (MNs) located in the brain stem motor nuclei,
spinal anterior horn neurons, and corticospinal tract, resulting in
paralysis and death within 3–5 years from the onset of symptoms.
In different population, the proportion of familial ALS (fALS)
ranges from 1 to 19%, while the remains are sporadic ALS
(SALS) with unknown cause (Rowland and Shneider, 2001).
To date, hundreds of mutations in more than 20 genes have
been implicated in the pathology of ALS, such as mutations
in superoxide dismutase (SOD1), TAR DNA-binding protein 43
(TARDBP), fusion (FUS), and a hexanucleotide expansion on
chromosome 9 in open reading frame 72 (C9ORF72). However,
these causative genes explain only two-thirds of fALS patients
and about 11% of SALS cases in Caucasian populations (Renton
et al., 2014).
Multiple mechanisms, including glutamate-mediated excite-
toxicity effects, abnormal astrocyte and microglial activation,
deficiency of neurotrophic factor secretion, protein misfolding,
and aggregations, mitochondrial dysfunction, rupture in the
axonal passage, destruction in calcium metabolism, changes
in skeletal proteins account for the selective vulnerability of
MNs, were implicated in the pathogenesis of ALS. However,
the exact mechanism underlying MNs death in ALS is still
unknown. Accumulating evidence indicates that dysregulation
of RNA processing pathway plays an important role in ALS
(Droppelmann et al., 2014).
RNA processing is a tightly regulated, highly complex
pathway, which includes RNA transcription, pre-mRNA splicing,
editing, transportation, translation, and degradation of RNA
(Bolognani and Perrone-Bizzozero, 2008). Several identified
causative genes of ALS are related to RNA metabolism, such
as angiogenin (ANG) (Gao and Xu, 2008), FUS (Kwiatkowski
et al., 2009), TARDBP gene (Strong et al., 2007). In addition,
several ALS-associated proteins, such as ELP3, SETX, were
reported to be involved in RNA processing (Strong, 2010).
Furthermore, the recent discovery of miRNAs, which are small
endogenous non-coding RNAs of 19–25 nucleotides functioned
as inhibitor mRNA translation of target protein-coding genes
or induce its degradation, has provided new insight into the
regulation of gene expression. Functional studies indicate that
miRNA plays a significant role in a broad range of cellular
and developmental processes, such as stem cell maintenance,
differentiation, development and energy metabolism (Bartel,
2009; Friedman et al., 2009).
Aberrant miRNAs expression has been implicated in several
neurodegenerative diseases, including ALS (Borovecki et al.,
2005; Hebert and De Strooper, 2009; Miñones-Moyano et al.,
2011; Cloutier et al., 2015). Different miRNA expression profiles
in ALS have been reported in several studies (Cloutier et al.,
2015). Up-regulation of miR-206 can slow down the progression
of ALS and promote regeneration of neuromuscular synapses,
but this up-regulation was also identified in other diseases, such
as schizophrenia (Hansen et al., 2007) and cerebral ischemia
(Jeyaseelan et al., 2008), suggesting that up-regulation of miR-206
is not specific for ALS. In addition, the limitations of previous
studies on miRNAs in ALS include small sample size (De Felice
et al., 2012; Campos-Melo et al., 2013; Ishtiaq et al., 2014),
the use of monogenic animal models (Butovsky et al., 2012;
Freischmidt et al., 2013; Marcuzzo et al., 2014; Nolan et al.,
2014), or human biopsy tissue from skeletal muscle (Russell
et al., 2012), spinal cord (Campos-Melo et al., 2013; Ishtiaq
et al., 2014) or frontal cortex (Shioya et al., 2010) which are
ethically unacceptable in life. Thus, a better understanding of
the involvement of miRNAs in ALS is required. On the other
hand, early diagnosis and management in specialized ALS clinics
providing multidisciplinary patient care has been shown to
positively impact quality of life and prolong survival of ALS
patients. However, delay in diagnosis for ALS has been widely
reported due to its significant overlap of clinical manifestations
with some clinically alike conditions at the early stage of
ALS (Andersen et al., 2012). Therefore, exploring the robust
biomarkers is essential for early diagnosis of ALS. Unlike other
biomarkers, miRNAs can be easily secreted into the extracellular
space from neurons and other CNS cells. Also, miRNAs are
isolated and quantified from a variety of biofluids, allowing
miRNAs as ideal potential biomarkers for ALS. However, in the
studiesmentioned above, the samples weremostly obtained at the
relatively end stage of the disease (De Felice et al., 2012; Ishtiaq
et al., 2014).
Considering the limited stability of specific brain-enriched
miRNAs due to the long interval for tissue samples to be
obtained, and the difficulties of obtaining samples from brain,
spinal cord or muscle (Sethi and Lukiw, 2009), it seems to be
of great advantage to test for biomarkers presented in peripheral
blood for diseases. Further evidence suggest that peripheral blood
gene and miRNAs expression could be used as indicators in
neurological diseases, such as Parkinson’s disease (PD) (Serafin
et al., 2015), Huntington’s disease (Borovecki et al., 2005), and
Alzheimer’s disease (Cheng et al., 2014). Moreover, in order
to avoid the effect of anticoagulation on the expression level
of miRNAs (Hastings et al., 2012), we investigated potentially
differential expression of miRNAs in leukocytes in SALS
patients.
METHODS
This study was approved by the Ethics Committee of West
China Hospital of Sichuan University, Chengdu, P.R. China, and
written informed consent was obtained from all subjects before
blood collection.
Subjects
The peripheral blood from SALS, PD and healthy controls
were obtained from the Department of Neurology, West China
Hospital of Sichuan University between May 2011 and October
2012. Clinically definite SALS patients were diagnosed based
on the EI Escorial revised criteria (Brooks et al., 2000) and
PD patients were diagnosed according to the United Kingdom
PD Society Brain Bank Clinical Diagnostic Criteria for PD
(Hughes et al., 1992). Revised ALS-FRS (ALSFRS-R) was used
Frontiers in Molecular Neuroscience | www.frontiersin.org 2 August 2016 | Volume 9 | Article 69
Chen et al. Aberration of miRNAs Expression in ALS
to assess the disease severity as our previous study (Chen
et al., 2014). To facilitate clinical interpretation of findings,
ALSFRS-R scores were categorized into three stages of severity:
mild or early (high, 37–48); moderate (medium, 25–36); and
severe or late (low, 0–24) (Kimura et al., 2006). The microarray
experiment included 5 SALS patients (3 males and 2 females)
and 5 age- and sex-matched healthy controls. The mean disease
duration of ALS patients was 15.19 ± 2.08 months (range
from 12.32 to 17.85 months), the ALSFRS-R of them was
40.20 ± 1.92 (range from 38 to 43), and the mean age of
SALS patients and controls was 50.75 ± 0.3 and 50.99 ±
0.5 years, respectively. Taqman Real Time-PCR experiments
were performed on an independent group including 83 SALS
patients, 24 PD patients and 61 healthy controls. All SALS
patients were followed up every 3 months from the first
registration.
Leukocytes Collection and RNA Extraction
Approximately 5 ml of whole blood was collected in EDTA-
containing tubes by venipuncture from all the participants
before clinical treatment was started in the morning. Within
2 h of the blood collection, the peripheral blood mononuclear
leukocytes (PBMCs) were separated via centrifuging with a
Ficoll-Paque PLUS (GE Healthcare Life Sciences, #17-1440-
02) according to the manufacturer’s instructions. Then, the
total RNA from PBMCs was isolated with a miRNeasy Mini
Kit (Qiagen, #217004). NanoDrop ND-1000 Spectrophotometer
(NanoDrop Technologies) was used to precisely measure the
concentration of RNA samples. The integrity of the RNA extracts
was measured using the Agilent Bioanalyzer 2100 (Agilent
Technologies Inc.).
miRNA Expression Profiling Analysis
The microarray hybridization of miRNAs was performed by
Capitalbio Corporation, China, using GeneChip miRNA 3.0
Array (Affymetrix) which contain a total of 1733 human sapiens
mature miRNA and 1658 human sapiens pre-miRNA probesets
that cover those miRNAs included in the Sanger miRBase v17
and miRBase miRNA (www.mirbase.org). A total of 130 ng
RNA from each sample of SALS patients and healthy controls
was used for each miRNA microarray. Affymetrix GeneChip
miRNA Array Procedure including: FlashTag RNA Labeling,
hybridization, Washing and Staining, scanning of the chips and
analysis of the results was carried out following the protocols
and equipment recommended by Affymetrix Inc. The software
used for processing chips and the results was the Affymetrix
GeneChip Command Console Software v3.0 (Affymetrix R©).
Data summarization, normalization, and quality control were
used by the free miRNA QC Tool software (Affymetrix R©), the
detail information of which is shown in its protocol (http://
media.affymetrix.com/support/downloads/manuals/mirna_qcto
ol_user_manual.pdf). Briefly, the probe intensity values were
background corrected, quantile-normalized, and the probeset-
level expression signals were summarized with the robust
multi-array average (RMA) method. The signal-to-noise ratio
optimization method was used to estimate the differential
expression for miRNAs, and the selection standard is as follow:
it is defined as up-regulated when the p < 0.05 and the ratio>2
(patients to controls), and it is defined as down-regulated when
the p < 0.05 and the ratio<0.5 (patients to controls; Seo et al.,
2004).
Validation Analysis by Quantitative
Real-Time PCR (qRT-PCT)
Selected miRNAs were validated in the validation phase (83
SALS, 24 PD, and 61 healthy controls) by using SYBR green
quantitative RT–PCR assay (Qiagen, Germany) (hsa-miR-34a,
hsa-miR-100, hsa-miR-193b, hsa-miR-4485, hsa-miR-3690, hsa-
miR-124, hsa-miR-183, hsa-miR-3935, hsa-miR-451, hsa-miR-
4538, and hsa-miR-4701). The process of quantification included
a two-step reaction: reverse transcription (RT) and PCR. Each
RT reaction consisted of 2 µl total RNA, 2 µl miScript Reverse
Transcriptase Mix (Qiagen, Germany), 2 µl miScript Nucleics
Mix (Qiagen, Germany), and 4 µl miScript HiSpec Buffer
(Qiagen, Germany), in a total volume of 20 µl. Reactions were
performed in a C1000 Thermal Cycler (Bio-Rad, USA) for 60min
at 37◦C, followed by heat-inactivation of RT for 5min at 95◦C.
The 20µl RT reactionmix was then diluted to 200µl in nuclease-
free water and held at−20◦C.
qRT-PCR was performed using Bio-Rad CFX96 Real-
Time PCR System (Bio-Rad, USA) with 20 µl PCR reaction
mixture that included 2 µl cDNA, 10 µl QuantiTect SYBR
Green PCR Master Mix (Qiagen, Germany), 2 µl miScript
Universal Primer (Qiagen, Germany), 2 µl miScript Primer
Assay (Qiagen, Germany), and 4 µl nuclease-free water.
Reactions were incubated in a 96-well optical plate at 95◦C
for 15min, followed by 40 cycles of 95◦C for 15 s, 55◦C for
30 s and 70◦C for 30 s. Each sample was run in triplicate
for analysis. At the end of the PCR cycles, melting curve
analyses were performed to validate the specific generation
of the expected PCR product. The expression changes of the
miRNAs were normalized to RNU6, and the difference was
calculated by the 11Ct method. The control group in each
comparison was used as a calibrator (11Ct = 0, 2−11Ct
= 1). Amplification efficiency for each miRNA was assessment
by technical duplicates method on a Bio-Rad Real-Time PCR
System.
Target Prediction and Gene Ontology (GO)
Analysis
The target genes for each significantly differentially regulated
miRNA were predicted by searching them on public databases
endowed with prediction algorithms, such as TargetScan
(http://targetscan.org), PicTar (http://pictar.mdc-berlin.de),
RNA22 (https://cm.jefferson.edu/rna22/Interactive/), PITA
(http://genie.weizmann.ac.il/pubs/mir07/mir07_data.html), and
Miranda (http://www.mirbase.org).
Gene Ontology analysis was applied to analyze the main
function of the differential expression genes according to the
Gene Ontology which is the key functional classification of
NCBI, which can organize genes into hierarchical categories and
uncover the gene regulatory network on the basis of biological
process and molecular function.
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Statistical Analysis
Data were expressed as mean ± standard deviation (SD) or
proportions. Student’s t-test and Fisher’s exact test were used
to determine the difference of clinical characteristics between
two groups. The differential expression levels of miRNAs
were compared using the Mann–Whitney U-test, and the p
values were corrected for multiple testing using the Benjamini–
Hochberg false discovery rate (FDR) method. Receiver operating
characteristics (ROC) curves and the area under the ROC curve
(AUC) were established to evaluate the diagnostic value of
miRNAs for differentiating patients from controls. An AUC
of 0.5 indicates classifications assigned by chance. Based on
ROC analysis, the best statistical cut-off values of miRNAs were
calculated, and the sensitivity and specificity for selected cut-off
points were then assessed. MedCalc (version 11.4.2.0; MedCalc,
Mariakerke, Belgium) software was used to perform the ROC and
regression analysis. All statistical analysis was performed using
Graphpad Prism 5.01 (Graphpad Software Inc., San Diego, CA,
USA). P-values of<0.05(two-tailed) were considered statistically
significant.
RESULTS
Clinical Characteristics
The clinical characteristics of participants were summarized in
Table 1. The mean age of SALS, PD and controls was 55.92 ±
7.38, 58.51 ± 5.60, and 54.20 ± 12.78 years, respectively.
The mean disease duration of SALS and PD was 17.33 ±
13.68 and 28.92 ± 12.84 months, respectively. There were
no significant differences in the distribution of sex among
SALS, PD, and healthy controls. During the time when we
analyzed the data of miRNAs expression, 58 patients died and
the mean survival time of ALS patients was 28.44 ± 15.96
months.
Identification of Differential miRNA
Profiling between ALS Patients and
Healthy Controls
A microarray containing probes for 3391 human miRNAs
(1733 mature and 1658 pre-miRNAs) was initially used to
screen the differential expression levels of miRNAs between
the SALS patients and healthy controls. Supplementary Figure
1 showed the hierarchical clustering of differential expressed
miRNAs between SALS and controls. Four miRNAs, including
hsa-miR-34a, hsa-miR-100, hsa-miR-193b, hsa-miR-4485, with
significantly higher expression levels were identified in the SALS
group compared with those in the healthy control group (mean
ratio = 2.11−3.12, p < 0.05, Table 2, Figure 1). Seven miRNAs
with significantly lower expression levels, including hsa-miR-
3690, hsa-miR-124, hsa-miR-183, hsa-miR-3935, hsa-miR-451,
hsa-miR-4538, and hsa-miR-4701, were identified in the SALS
group compared with HCs (mean ratio = 0.35–0.43, p < 0.05,
Table 2, Figure 1).
Validation Analysis by Quantitative
Real-Time PCR
In order to avoid the false-positive results obtaining from
microarray, we performed additional real-time PCR for all of
the 11 identified different expressed miRNAs in an independent
cohort, including 83 SALS and 61HCs to validate. The expression
patterns of these miRNAs were analyzed using quantitative
real-time PCR (qRT-PCR). The significant differences in the
expression levels of four miRNAs (hsa-miR-183, hsa-miR-193b,
hsa-miR-451, and hsa-miR-3935) were confirmed between the
SALS patients and HCs (Figure 2). It is noteworthy that the hsa-
miR-193b showed opposite direction of relative expression with
microarray analysis in the validation stage.
There were no significant differences in the expression levels
of the four miRNAs between patients with spinal-onset and
TABLE 1 | General characteristic of the study subjects for validation study.
SALS PD HCs
Cases, n 83 24 61
Sex, female (%) 37 (44.58%) 10 (41.66%) 27 (44.26%)
Mean age (mean ± SD, years) 55.92 ± 7.38 58.51 ± 5.60 54.20 ± 12.78
Mean onset age (mean ± SD, years) 54.49 ± 6.35 56.67 ± 4.87 −
Disease duration* (mean ± SD, months) 17.33 ± 13.68 28.92 ± 12.84 −
Mean ALSFRS-R 38.50 ± 6.22 − −
INITIAL SYMPTOMS
Bulbar 16 − −
Upper limb 47 − −
Lower limb 20 − −
ONSET AGE
≤40 years 12 − −
>40 years 71 − −
Disease duration# (mean ± SD, months) 28.44 ± 15.96 − −
*Mean disease duration from onset to collection in all SALS patients.
#Mean disease duration from onset to death in 58 SALS.
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bulbar-onset, between patients with disease duration within 1
year and within 1–2 years, between patients with early onset
(≤40 years) and late onset (>40 years), and between patients with
different sex. In addition, no correlation was found between the
TABLE 2 | Differentially expression miRNAs identified by microarray
analysis in leukocytes between SALS and controls.
Differentially expression type microRNA name Mean ratio
Up-regulated hsa-miR-193b 2.1165
hsa-miR-34a 3.1282
hsa-miR-100 2.3189
hsa-miR-4485 2.6155
Down-regulated hsa-miR-3690 0.4276
hsa-miR-124 0.3538
hsa-miR-183 0.3946
hsa-miR-3935 0.3999
hsa-miR-451 0.4126
hsa-miR-4538 0.3603
hsa-miR-4701 0.4249
expression levels of the four miRNAs and disease duration from
onset to death (data not shown).
The ROC curve analyses revealed that the levels of hsa-
miR-183, hsa-miR-193b, hsa-miR-451, and hsa-miR-3935 were
useful biomarkers for the diagnosis of ALS, with AUC values
of 0.763 [95%CI: 0.677–0.835], 0.713 [95%CI: 0.624–0.792],
0.820 [95%CI: 0.740–0.884], and 0.590 [95%CI: 0.497–0.679],
respectively. Among the four miRNAs, hsa-miR-193b had the
highest specificity with the cut-off value of 0.7675, and hsa-
miR-3935 had the highest sensitivity when its cut-off value is
4.2734 (Table 3). The four miRNAs were combined as a panel
of miRNAs by the logit model, which was used to construct the
ROC curve as follow, logit (p = SALS) = 3.152 − 0.708 × hsa-
miR-193b − 1.517 × hsa-miR-183 − 0.147 × has-miR-3935 −
3.331 × hsa-miR-451. The calculated AUC for the miRNA panel
was 0.857 (95%CI: 0.782–0.914, sensitivity= 89.9%, specificity=
65.4%, Table 3, Figure 3).
In order to assess whether the four different expression
miRNAs were specific in ALS, the expression levels of the
four miRNAs were tested in 24 PD patients. The expression of
hsa-miRNA-183 showed no difference between PD patients and
HCs, but was significantly lower in SALS patients than that in
FIGURE 1 | Hierarchical clustering analysis between 5 SALS patients and 5 healthy controls based on differentially expressed miRNAs. The horizontal
rows represent the 11 differentially expressed microRNAs, and the columns represent the 10 samples, 5 from the SALS (A) and 5 from the healthy controls (C). Red
indicates relative overexpression, and green indicates relative underexpression.
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FIGURE 2 | Validation of miRNAs expression by qRT-PCR analysis in leukocytes samples from SALS (n = 83) and HCs (n = 61). Data are represented by
bar chart. The P-values were calculated by the Mann-Whitney U-test. The relative expression of miRNAs in HCs was normalized.
PD patients. The expression of hsa-miR-451 and hsa-miR-3935
were significantly lower in PD patients than those in SALS and
controls. There was no significant difference in the expression of
hsa-miR-193b between PD patients and HCs, and between SALS
patients and PD patients (Table 4).
Target Prediction and Gene Ontology (GO)
Analysis
By public miRNA target databases, 182 genes that were predicted
to be target genes of at least 2 miRNAs in these four miRNAs
(Supplementary Figure 1 and Supplementary Table 1 [miRNAs-
target genes]) were obtained. A functional network (Figure 4
and Supplementary Table 1 [miRNAs-pathways]), based on Gene
Ontology and KEGG database, was constructed to visualize the
connections of hsa-miR-183, hsa-miR-193b, hsa-miR-3935, and
their predicted targets (hsa-miR-451, which target genes were less
and failed to construct the pathway net, was rule out). Forty-
five pathways were constructed, including 16 pathways linked
to the two miRNAs, among which PI3K-Akt signaling pathway
(map04151), mTOR signaling pathway (map04150), regulation
of actin cytoskeleton (map04810), axon guidance (map04360),
MAPK signaling pathway (map04010), glioma (map05214), and
gap junction (map04540), were associated with the pathogenic
mechanism with neurodegenerative diseases.
DISCUSSION
In this study, we were the first to report a comprehensive array-
based miRNA expression profile in the peripheral blood of SALS
patients from Han Chinese. We observed four down-regulated
miRNAs in SALS contrasted with that in healthy controls and
found that hsa-miRNA-183 might be a specific biomarker for
SALS.
According to the results of our previous study (Yang et al.,
2011), the mean survival time of SALS patients was 32.44 ±
19.63 months and the median survival time was 29.67 months.
However, the survival time of ALS patients is much shorter in
our cohort than that in Caucasian populations (Martínez et al.,
2011). Besides the disparity of the medical condition, delay in
diagnosis is an important factor affecting the mean survival time.
Previous retrospective studies found a delay from symptom onset
to diagnosis ranges from 8 to 15.6 months (Cellura et al., 2012).
Another study reported that more than half of ALS patients
received an alternative diagnosis and each patient saw an average
of three different physicians before ALS diagnosis was confirmed
(Paganoni et al., 2014). Moreover, time to diagnosis are longer for
patients with limb-onset, older age, or sporadic form (Paganoni
et al., 2014). In China, fewer neurologists were available for the
same population-based community comparing with that in the
developed countries. Therefore, discovery of an accurate and
sensitive biomarker is of utmost importance in current ALS
research. Biomarkers in blood are the primary consideration due
to its advantages of non-invasive, easy handling and multiple
testing at a low cost. Further, the steady miRNAs is a more
promising potential biomarker than cytokines and growth factors
in plasma and serum.
MiRNAs, as a key regulator, was first reported by Williams
et al. That study showed that miR-206 slowed ALS progression
and promoted regeneration of neuromuscular synapses in mice
model (Williams et al., 2009). Ever since, numerous studies
about miRNAs in ALS have been conducted, the samples were
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TABLE 3 | miRNAs profile and diagnostic performance in training dataset.
micRNAs p-valve AUC 95%CI Z statistic Criterion Sensitivity (%) Specificity (%)
hsa-miR-193b 0.006 0.713 0.624–0.792 4.592 ≤0.7675 53.6 84.6
hsa-miR-183 0.001 0.763 0.677–0.835 6.043 ≤0.3727 73.9 71.2
hsa-miR-3935 <0.001 0.590 0.497–0.679 1.646 ≤4.2734 100 25.0
hsa-miR-451 0.001 0.820 0.740–0.884 8.361 ≤0.2557 85.5 69.2
Combination* 0.857 0.782–0.914 10.818 > −0.0929 89.9 65.4
*Logit (p = SALS) = 3.152 − 0.708 × hsa-miR-193b − 1.517 × hsa-miR-183 − 0.147 × has-miR-3935 − 3.331 × hsa-miR-451.
obtained from cultured cells, animal model and ALS patients, and
the tissues included blood, cerebral spinal fluid (CSF), muscle,
spinal cord, and brain (Cloutier et al., 2015). However, as a
biomarker, miR-206 was reproduced by only one study, which
reported that miR-206 was up regulated in serum from SOD1
ALS mice and ALS patients (Toivonen et al., 2014). Except for
this study, few miRNAs were reproduced in the following studies
whether microarray or qRT-PCR based. Possible explanations
for these different results included detection methods, sample
size, resource of tissue, disease course, familial or sporadic form,
and ethnic origin. Some studies only used microarray method
without verifying the facticity; some studies only applied qRT-
PCR method without discovering the novel miRNAs; while
other studies recruited patients or controls less than 10, which
easily resulted in false positive or false negative findings.
Furthermore, miRNAs expressions may varied at different stages
as the disease progresses, the different expression of miRNAs
in fALS patients could not be reproduced in SALS patients
probably due to the specific defective genes in fALS, and a
more heterogeneous of miRNAs in SALS compared with fALS
were identified (Freischmidt et al., 2015). Thus, the expression
of miRNAs might be regulated by some upstream genes, the
epigenetic modifications, which were by mediated in different
genetic background. In the present study, using the methods of
combining microarray and qRT-PCR, we first detected miRNAs
in Chinese SALS population. These miRNAs, including hsa-
miR-183, hsa-miR-193b, hsa-miR-451, and hsa-miR-3935, were
down regulated in SALS patients relative to healthy controls,
with AUC values of 0.69, 0.62, 0.81, and 0.57, respectively.
Interestingly, in the subgroup analysis, no significant differences
in the expression levels of these four miRNAs were found,
according to clinical presentations of ALS, such as site of onset
(spinal or bulbar), age of onset (early or late), disease duration
(within one year and within 1–2 years), and gender. Our finding
may indicate that these miRNAs could provide a new promising
opportunity for detection of SALS. Combining the expression
of these four miRNAs in PD, the results suggested that hsa-
miRNA-183 might be a specific biomarker for SALS, whereas
hsa-miR-451 and hsa-miR-3935 might be common biomarkers
linked to neurodegenerative diseases, such as ALS and PD.
However, these need to be confirmed in further related studies
with other neurodegenerative diseases and a larger number of
participants.
There is growing evidence suggesting that specificmiRNAs are
involved in the development and progression of ALS through the
FIGURE 3 | ROC curve analysis using differential expressive miRNAs
for discriminating SALS. ROC curve analyses revealed that the plasma
levels of hsa-miR-183, hsa-miR-193b, hsa-miR-451, and hsa-miR-3935 were
useful biomarkers for differentiating SALS and HCs, with AUC values of 0.763,
0.713, 0.820, and 0.590, respectively. When the four miRNAs were combined
by logistic regression model, the AUC values for differentiating SALS and HCs
were 0.857.
regulation of broad signaling pathway, including inflammation
(Butovsky et al., 2012; Parisi et al., 2013), neurofilament
(Campos-Melo et al., 2013; Ishtiaq et al., 2014), mitochondrial
function (Russell et al., 2012), endoplasmic reticulum (ER)
stress (Nolan et al., 2014) and others complex network of
miRNAs (Shinde et al., 2013). The miR-29a-special antagomir,
demonstrated increased lifespan in male SOD1G93A mice by
reducing ER stress (Nolan et al., 2014); Inhibition of miR-
23a ameliorates skeletal muscle mitochondrial function in ALS
by increasing the PGC-1α signaling, which was involved in
mitochondrial biogenesis and function (Russell et al., 2012); the
anti-miR-155 significantly extends survival and disease duration
in the SOD1G93A mouse model (Koval et al., 2013), and the
miR-206 delays ALS progression and promotes regeneration of
neuromuscular synapses inmice partly through fibroblast growth
factor and histone deactylase 4 signaling pathways (Williams
et al., 2009). In the present study, we observed significantly
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TABLE 4 | Different expression of all four miRNAs in SALS patients, PD patients, and healthy control subjects.
miRNAs SALS PD HCs p-valuea p-valueb p-valuec
hsa-miR-183 0.338 ± 0.2370 1.5258 ± 1.0873 0.7406 ± 0.7409 <0.0001 0.001 0.3887
hsa-miR-193b 1.1993 ± 0.7731 1.3179 ± 0.8240 1.6722 ± 1.1496 0.5533 0.006 0.184
hsa-miR-451 0.193 ± 0.1583 0.1161 ± 0.0746 0.5935 ± 0.5139 0.0084 <0.0001 <0.0001
hsa-miR-3935 1.5258 ± 1.0873 0.8964 ± 0.3793 6.5546 ± 8.7273 0.0008 0.001 <0.0001
aDifferent expression between SALS and PD patients.
bDifferent expression between SALS patients and healthy control subjects.
cDifferent expression between PD patients and healthy control subjects.
FIGURE 4 | miRNA-pathway signal-net analyses.
lower expression of hsa-miR-183, hsa-miR-193b, hsa-miR-451,
and hsa-miR-3935 in SALS patients compared with controls.
By target prediction and GO analysis, we found low levels of
these miRNAs may ease post-transcriptional suppression of their
up-regulated mRNA targets related to several neurodegenerative
signaling pathway, including PI3K-Akt signaling pathway (hsa-
miR-183 andhsa-miR-193b), mTOR signaling pathway (hsa-
miR-193b and hsa-miR-3935), regulation of actin cytoskeleton
(hsa-miR-193b and hsa-miR-3935), axon guidance (hsa-miR-
193b and hsa-miR-3935), MAPK signaling pathway (hsa-miR-
183 andhsa-miR-3935) and so on. The differential expression
of miR-183 was found in several cancers, including prostate
cancer (Yuan et al., 2015), gastric cancer (Cao et al., 2014),
breast cancer (Lowery et al., 2010), which may be involved
in cell proliferation, migration and invasion (Zhu et al., 2012;
Lu et al., 2015). The miR-183-96-182 cluster regulates multiple
biological programs that converge to support the maintenance
and metastatic potential of medulloblastoma coupled to the
PI3K/AKT/mTOR pathway (Weeraratne et al., 2012). Previous
studies also found that survival motor neuron (SMN) gene
regulates axonal local translation via miR-183/mTOR pathway,
which contributed to spinal muscular atrophy pathology (Kye
et al., 2014). Thus, dysregulation of miR-183 may be involved in
progressive loss of motor neurons in ALS. Similarly, the miR-
193b was also reported to modulate cell proliferation (Chen
et al., 2010; Gao et al., 2011), migration, and invasion (Hu
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et al., 2012), and downregulation of miR-193b contributes to
enhanced tumor progression and invasion through its target
gene-neurofibromin 1(NF1) (Li et al., 2009; Lenarduzzi et al.,
2013). The NF1 is required for appropriate granule neuron
progenitor expansion and migration in cerebellar development
through regulation of RAS/ERK signaling (Sanchez-Ortiz et al.,
2014). Moreover, previous study found the miR-193b may take
part in the development of AD and is a potential blood-based
biomarker of mild cognitive impairment and AD (Liu et al.,
2014). However, the accurate mechanisms of the miR-193b
causing neurodegeneration remained unknown. Previous studies
found that the miR-451, which was differentially expressed in
several diseases, such as multiple myeloma (Du et al., 2015),
epithelial ovarian cancer (Ling et al., 2015), and central nervous
system malignancies (Drusco et al., 2015), could represses cell
proliferation and invasion (Zeng et al., 2014). In SH-SY5Y
neuron-like cells, downregulation of miR-451 had neurotrophic,
neuroprotective, anti-Oxidant, and anti-apoptotic effects (Alural
et al., 2014). Interestingly, the down-regulation of hsa-miR-451
was also found in leukocytes from Italian ALS patients (De Felice
et al., 2012). In the present study, we observed down-regulation
of hsa-miR-451 in our SALS and PD patients, suggesting that the
miRNA might be a biomarker for neurodegenerative diseases,
which was not specific to SALS. However, little is known about
the function and role of miR-3935. In the current study, the
down-regulation of miR-3935 was found not only in SALS but
also in PD compared with healthy controls, indicating that miR-
3935 miRNA might be related to neurodegeneration.
However, we must consider some limitations of the current
study. First, only one sample per patient was test in microarray
analysis study, which was one of confounding factors resulting
in the relatively high variability of miRNAs expression, although
the quality of each sample of subjects were strictly tested.
Second, for the potential candidate biomarker study, longitudinal
data providing is important. Regrettably, the blood sample for
each subject was collected only once in the current study. The
expression profiling of ALS during disease progression should be
tested in the future studies. Thirdly, only PD patients besides ALS
were enrolled in the validation stage analysis for comparation,
therefore other neurodegenerative disorders such as AD and
FTD and so on should be compared. And whether alteration
of these miRNAs in the CNS should be tested in the future
studies.
In summary, our pilot study showed that peripheral blood
leukocytesmiR-183,miR-193b,miR-451, andmiR-3935 are down
regulated in SALS, which raises the potential clinical utility
of leukocytes miRNA profiling in SALS diagnosis. Although,
such approach is technically challenging, we believe that the
leukocytes miRNAs could be a promising diagnostic tool for
SALS. Further investigations are required to figure out the
underlying mechanisms of how the change of miRNAs level in
leukocytes reflect the pathology of motor neuron, as well as their
biological functions.
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